Chłopiec chory na SMA
EN_01552308_0003
A weekly scheduling marker board for Levi de Oliveira Balbino, 2, who received an infusion of Zolgensma, a cutting edge gene therapy for his spinal muscular atrophy (SMA) that can cost more than $1 million, at his family's home outside of Recife, Brazil, June, 4, 2022. A wave of transformative but hugely expensive treatments is challenging the budgets of health coverage systems in both wealthy nations and some countries with far fewer resources. (Dado Galdieri/The New York Times)
Minimum price 100USD
2022-06-04
DADO GALDIERI/The New York Times Agency/East News
The New York Times Agency
DADO GALDIERI
15793693
8,71MB
42cm x 28cm przy 300dpi
1, 2, 2022, 4, A, AMERICA, AN, AND, AT, ATROPHY, BALBINO, BOARD, BOTH, BRAZIL, BUDGETS, BUT, CAN, CHALLENGING, COST, COUNTRIES, COVERAGE, CUTTING, DADO, DE, DISEASE, DISORDER, EDGE, EXPENSIVE, FAMILY, FAR, FEWER, FOR, GALDIERI, GENE, GENETIC, GOVERNMENT, HEALTH, HIS, HOME, HUGELY, IN, INFUSION, IS, JUNE, LEVI, MARKER, MEDICAL, MEDICATIONS, MILLION, MORE, MUSCULAR, NATIONS, NEW, OF, OLIVEIRA, OUTSIDE, PRICE, RARE, RECEIVED, RECIFE, RESOURCES, S, SCHEDULING, SMA, SOME, SOUTH, SPINAL, SYSTEMS, THAN, THAT, THE, THERAPIES, THERAPY, TIMES, TRANSFORMATIVE, TREATMENTS, WAVE, WEALTHY, WEEKLY, WHO, WITH, YORK, ZOLGENSMA,